A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Hansa Biopharma AB30 enrolled

Overview

The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients. The patients in this study will be treated with the study medicine imlifidase on day 1, and with IVIg on days 3-7. The purpose of this study is to investigate the safety and effectiveness of imlifidase in patients diagnosed with GBS.

This is an open-label, single arm, multi-centre, phase II study of imlifidase in combination with standard care IVIg in patients with GBS. The study will recruit approximately 30 patients who are eligible for IVIg treatment based on current practice (i.e. GBS disability score \>3 and within 10 days of onset of weakness). All patients will receive imlifidase (Day 1) prior to standard care IVIg. There is growing body of evidence suggesting that GBS is an antibody-mediated disorder. In addition to supportive care, IVIg and Plasma Exchange (PE) are the two main immunological treatment options aimed at attenuating the autoreactive humoral immune response. Imlifidase is an IgG degrading enzyme with strict specificity. The hypothesis is that reduction of pathological antibodies may result in aborted progression, quicker recovery and less severe disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Guillain-Barré Syndrome (GBS)

Interventions

ImlifidaseDRUG

All subjects will receive imlifidase (Day 1) prior to standard care IVIg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Signed Informed Consent obtained before any study-related procedures. 2. Willingness and ability to comply with the protocol. 3. Male or female aged ≥18 years at the time of screening. 4. GBS diagnosed according to National Institute of Neurological Disorders and Stroke (NINDS) diagnostic criteria (Asbury et al. 1990). 5. Onset of weakness due to GBS is not more than 10 days prior to screening. 6. Unable to walk unaided for \>10 meters (grade ≥ 3 on GBS DS). 7. IVIg treatment being considered. 8. Women of child-bearing potential willing or able to use at least one highly effective contraceptive method from the day of treatment until at least 6 months after the dose of imlifidase if not abstinent. In the context of this study, an effective method is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly. 9. Men willing to use double-barrier contraception from the day of treatment until at least 2 months after the dose of imlifidase if not abstinent. Exclusion Criteria: 1. Previous treatment with imlifidase. 2. Previous IVIg treatment within 28 days prior to imlifidase treatment. 3. Subjects who are being considered for, or already on, PE. 4. Women of child-bearing potential willing or able to use at least one highly effective contraceptive method from the screening visit until at least 180 days following imlifidase dosing. 5. Breastfeeding or pregnancy 6. Clinical evidence of a polyneuropathy of another cause e.g. diabetes mellitus (except mild sensory), alcoholism, vitamin deficiency, or porphyria. 7. Known selective immunoglobulin A (IgA) deficiency. 8. Hypersensitivity to IVIg or to any of the excipients. 9. Immunosuppressive treatment (e.g. azathioprine, cyclosporine, mycophenolate mofetil, tacrolimus, sirolimus or \> 20 mg prednisolone daily) during the last month. 10. Subject known to have a severe concurrent disease, e.g. malignancy, severe cardiovascular disease and severe chronic obstructive pulmonary disease (COPD). 11. Any condition that in the opinion of the investigator could increase the subject's risk by participating in the study or confound the outcome of the study. 12. Known mental incapacity or language barriers precluding adequate understanding of the Informed Consent information and the study activities. 13. Subjects with clinical signs of ongoing infection. 14. Subjects should not have received other investigational drugs within 5 half-lives prior to imlifidase dosing. 15. Present or history of thrombotic thrombocytopenic purpura (TTP), or known familial history of TTP. 16. Positive PCR test for SARS-CoV-2 virus infection.

Locations (11)

CHU Le Kremlin-Bicêtre. Service Neurologie

Le Kremlin-Bicêtre, Paris, France

CHU Bordeaux - Hôpital Pellegrin Tripode

Bordeaux, France

CHU de Limoges - Hôpital Dupuytren

Limoges, France

Outcomes

Primary Outcomes

Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 1 Grade

Efficacy is assessed as proportion of subjects with improvement of one (1) or more grades in disability outcome on the 6-point GBS DS over time. The 6-point Guillain Barré Syndrome disability score (GBS DS) is a widely accepted and easily obtainable scoring system used to assess disability status of GBS subjects. The DS score is as follows: 0=Healthy, 1=Minor symptoms and capable of running (subjects must be asked to run), 2=Able to walk independently 10 meters or more but unable to run, 3=Able to walk more than 10 meters across an open space with help, 4=Bedridden or chair bound, 5=Needing mechanical ventilation, 6=Dead

Time frame: Baseline to Day 360

Guillain Barré Syndrome Disability Score (GBS DS) - Time to Improve by at Least 2 Grades

Time frame: Baseline to Day 360

Guillain Barré Syndrome Disability Score (GBS DS) - Ability to Walk Unaided

Efficacy is assessed as proportion of subjects able to walk unaided (i.e. GBS DS=2) over time

Time frame: Baseline to Day 360

Proportion of Patients Who Are Able to Run Over Time (GBS DS≤1)

Efficacy is assessed as proportion of patients able to run (i.e. Guillain Barré Syndrome disability score \[GBS DS\] ≤1) over time

Time frame: Baseline to Day 360

Mean MRC Sum Score Over Time

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Hôpital de la Timone - Centre de référence des maladies neuromusculaires et de la SLA

Marseille, France

CHU de Montpellier, Hôpital Gui de Chauliac

Montpellier, France

Centre Hospitalier Universitaire de Nantes

Nantes, France

Service de neurologie, Hôpitaux Universitaires de Strasbourg

Strasbourg, France

Amsterdam UMC

Amsterdam, Netherlands

Erasmus Medical Centre

Rotterdam, Netherlands

Queen Elizabeth University Hospital Glasgow

Glasgow, United Kingdom

...and 1 more locations

Efficacy is assessed as Medical Research Council (MRC) sum score over time. The MRC sum score is widely used to assess the motor impairment in subjects with peripheral neuropathies. It is a sum score of power in 6 muscle groups on each side (abduction of arm, flexion of forearm, extension of the wrist, hip flexion, and extension of knee and dorsal flexion of the foot). The sum of these scores ranges from 0 (total paralysis) to 60 (normal power). It provides valuable information about the muscle strength. Change in MRC sum score helps in identification of GBS patients with treatment related fluctuation or exacerbation. The individual MRC grades are defined as follows: 0=No visible contraction,1=Visible contraction without movement of the limb, 2=Movement of the limb but not against gravity, 3=Movement against gravity (almost full range), 4=Movement against gravity and resistance, 5=Normal

Time frame: Baseline until Day 180

Change From Baseline in MRC Sum Score Over Time

Efficacy is assessed as change in Medical Research Council (MRC) sum score. The MRC sum score is widely used to assess the motor impairment in subjects with peripheral neuropathies. It is a sum score of power in 6 muscle groups on each side (abduction of arm, flexion of forearm, extension of the wrist, hip flexion, and extension of knee and dorsal flexion of the foot). The sum of these scores ranges from 0 (total paralysis) to 60 (normal power). It provides valuable information about the muscle strength. Change in MRC sum score helps in identification of GBS patients with treatment related fluctuation or exacerbation. The individual MRC grades are defined as follows: 0=No visible contraction,1=Visible contraction without movement of the limb, 2=Movement of the limb but not against gravity, 3=Movement against gravity (almost full range), 4=Movement against gravity and resistance, 5=Normal

Time frame: Baseline until Day 180

Mean R-ODS Over Time

The patients have rated their ability to perform different common activities using the Rasch-built overall disability score (R-ODS) questionnaire. R-ODS is a linearly weighted disease specific scale, which captures activities and social participation limitation in patients with immune-mediated neuropathies, including GBS. The questionnaire comprises 24 items ranging from ability to read a book or newspaper (as the easiest item to accomplish) to ability to run (most difficult item to accomplish). The response options for each item are: 0=Not possible, 1=Possible with effort, 2=Easy to perform. The obtained raw summed score is subsequently translated to a centile metric ranging from 0 (most severe disability) to 100 (no disability at all).

Time frame: Baseline to Day 360

Change From Baseline in R-ODS Over Time

Time frame: Baseline to Day 360

Days in Hospital

The number of days the patients were admitted to hospital

Time frame: Baseline to Day 360

Time in an ICU

Efficacy is assessed as time in an intensive care unit (ICU)

Time frame: Baseline until Day 360

Need for Mechanical Ventilation

Time frame: Baseline until Day 180

Patient's Health State Over Time as Assessed by EQ VAS

Quality of Life will be assessed using the EurQol group's EurQol - 5 dimension (EQ-5D) Health questionnaire. The EQ-5D consists of 2 parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ VAS records the patient's self-rated health on a vertical scale, where score 100 is 'The best health you can imagine' and score 0 is the 'The worst health you can imagine'.

Time frame: Day 8, Day 15, Day 29, Day 57, Day 92, Day 180, and Day 360